Live, oral, heat Stable S. typhi TY21a vaccine
Award amount
$974,606Program and phase
SBIR · Phase IAward year
2005Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Aridis Pharmaceuticals, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LA2ZAQNZE6W5
- Solicitation number
- PHS2005-2
- Topic code
- Not reported
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Stable Vaccines Delivered on Oral Thin Films
- Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis
- Inhalable Gallium Nitrate Anti-Infective Powder for CF
- Human Monoclonal Antibody To Treat P. aeruginosa Infections in Cystic Fibrosis
Research funding history
5 SBIR/STTR records share this UEI (2005–2014). Reported award amounts total $5,363,118. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services